Hepatitis B virus surface antigen selectively inhibits TLR2 ligand-induced IL-12 production in monocytes/macrophages by interfering with JNK activation

J Immunol. 2013 May 15;190(10):5142-51. doi: 10.4049/jimmunol.1201625. Epub 2013 Apr 12.

Abstract

It is widely accepted that chronic hepatitis B virus (HBV) infection is the result of an ineffective antiviral immune response against HBV infection. Our previous study found that the hepatitis B surface Ag (HBsAg) was related to decreased cytokine production induced by the TLR2 ligand (Pam3csk4) in PBMCs from chronic hepatitis B patients. In this study, we further explored the mechanism involved in the inhibitory effect of HBsAg on the TLR2 signaling pathway. The results showed that both Pam3csk4-triggered IL-12p40 mRNA expression and IL-12 production in PMA-differentiated THP-1 macrophage were inhibited by HBsAg in a dose-dependent manner, but the production of IL-1β, IL-6, IL-8, IL-10, and TNF-α was not influenced. The Pam3csk4-induced activation of NF-κB and MAPK signaling were further examined. The phosphorylation of JNK-1/2 and c-Jun was impaired in the presence of HBsAg, whereas the degradation of IκB-α, the nuclear translocation of p65, and the phosphorylation of p38 and ERK-1/2 were not affected. Moreover, the inhibition of JNK phosphorylation and IL-12 production in response to Pam3csk was observed in HBsAg-treated monocytes/macrophages (M/MΦs) from the healthy donors and the PBMCs and CD14-positive M/MΦs from chronic hepatitis B patients. Taken together, these results demonstrate that HBsAg selectively inhibits Pam3csk4- stimulated IL-12 production in M/MΦs by blocking the JNK-MAPK pathway and provide a mechanism by which HBV evades immunity and maintains its persistence.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anthracenes / pharmacology
  • Cell Differentiation
  • Cell Line, Tumor
  • Enzyme Activation
  • Extracellular Signal-Regulated MAP Kinases / metabolism
  • Hepatitis B Surface Antigens / immunology
  • Hepatitis B Surface Antigens / metabolism*
  • Hepatitis B virus / immunology
  • Hepatitis B, Chronic / immunology
  • Hepatitis B, Chronic / virology
  • Humans
  • I-kappa B Proteins
  • Immune Evasion / immunology*
  • Interleukin-10 / biosynthesis
  • Interleukin-12 / biosynthesis
  • Interleukin-12 / metabolism*
  • Interleukin-12 Subunit p40 / biosynthesis
  • Interleukin-12 Subunit p40 / genetics
  • Interleukin-1beta / biosynthesis
  • Interleukin-6 / biosynthesis
  • Interleukin-8 / biosynthesis
  • JNK Mitogen-Activated Protein Kinases / immunology
  • JNK Mitogen-Activated Protein Kinases / metabolism*
  • Lipopeptides / metabolism
  • Macrophages / metabolism
  • Monocytes / metabolism
  • NF-KappaB Inhibitor alpha
  • NF-kappa B / metabolism
  • Phosphorylation
  • RNA, Messenger / genetics
  • RNA, Messenger / metabolism
  • Toll-Like Receptor 2 / immunology
  • Toll-Like Receptor 2 / metabolism*
  • Transcription Factor RelA / metabolism
  • Tumor Necrosis Factor-alpha / biosynthesis

Substances

  • Anthracenes
  • Hepatitis B Surface Antigens
  • I-kappa B Proteins
  • Interleukin-12 Subunit p40
  • Interleukin-1beta
  • Interleukin-6
  • Interleukin-8
  • Lipopeptides
  • NF-kappa B
  • NFKBIA protein, human
  • Pam(3)CSK(4) peptide
  • RNA, Messenger
  • TLR2 protein, human
  • Toll-Like Receptor 2
  • Transcription Factor RelA
  • Tumor Necrosis Factor-alpha
  • Interleukin-10
  • NF-KappaB Inhibitor alpha
  • Interleukin-12
  • pyrazolanthrone
  • Extracellular Signal-Regulated MAP Kinases
  • JNK Mitogen-Activated Protein Kinases